SEC Form 4 · accession 0001493152-18-002844
PetLife Pharmaceuticals, Inc. · PTLF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ralph T Salvagno
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Aug 17, 2017
Accepted (ET)
Mar 2, 2018 · 3:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001354591
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 17, 2017 | J | 1,250,000 | — | D | 12,450,000 | I | By Grand Street Ventures, LLC |
| Series A Preferred StockF1 | Aug 17, 2017 | J | 1,250,000 | — | A | 1,250,000 | I | By Grand Street Ventures, LLC |
| Common StockF2,F1 | Aug 17, 2017 | A | 5,000,000 | $0.06 | A | 17,450,000 | I | By Grand Street Ventures, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Conversion of common stock into Series A preferred stock on a 1:1 basis.
- F2Accrued compensation converted into common stock at a conversion rate of $0.06/share.